Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1231 - A survey of on platinum ineligible in head and neck cancer patients in India (520P)


18 Nov 2017


Poster lunch


Dilip Pawar


Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676


D. Pawar1, R. Ahmed2, S. Chaudhari2

Author affiliations

  • 1 Medical Affairs And Clinical Development, Biocon Limited, 560100 - Bangalore/IN
  • 2 Medical Affairs, Biocon Limited, 560100 - Bangalore/IN


Abstract 1231


Majority of the patients of head and neck cancer (HNC) that are treated with anticancer chemotherapy receive platinum based drugs. However, few patients cannot tolerate toxicity of these agents and hence are ineligible for platinum based chemotherapy. Treatment options for such patients are limited and outcomes are usually poor


We conducted a questionnaire based survey in 2016 among oncologists across India to understand routine clinical practice related to management of platinum ineligible patients. A questionnaire of 10 questions was prepared and circulated amongst 50 oncologists across India. Responses from 36 doctors were analysed.


Majority of doctors believe that clinical factors for considering a patient unfit for platinum based chemotherapy are age (61.1%), renal function (58.3%), performance status (33.3%), comorbid conditions (19.4%). Comorbid conditions that are considered before giving platinum based drugs to such patients are age (30.6%), diabetes (27.8%), cardiovascular function (30.6), renal function (38.9%). 91.7% doctors believe that functional age is a critical factor in such patients. Cut off age for platinum based treatment was stated to be 55 by 2.7%, 60 by 19.4%, 65 by 38.8%, 70 by 25% doctors. Methods used to reduce toxicity of platinum based chemotherapeutic agents include hydration (44.4%), supportive measures and drugs (11.1%), using alternative chemotherapy agents like carboplatin (8.3%), diuretics (8.3%), low dose therapy (11.1%). 69.3% doctors believe that additional nutritional support from the time of diagnosis will help convert platinum ineligible patients fit for platinum based treatment. In doctors opinion Carboplatin is given to 21.9% patients, docetaxel in 15.9% patients, paclitaxel in 10.3%, cituximab in 15.1%, nimotuzumab in 36.2% are given to such patients with radiotherapy.15.1% patients receive only radiotherapy.


Several factors render a patient unfit for platinum based chemotherapy. However no standard protocol is available to define patients ineligible for platinum based chemotherapy. Defining criteria for platinum ineligible patients will help in better decision making in day to day clinical practice and improve treatment outcomes

Clinical trial identification


Legal entity responsible for the study

Dr Dilip Pawar




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.